about
Asymmetry of the endogenous opioid system in the human anterior cingulate: a putative molecular basis for lateralization of emotions and pain.HIV-1 Tat exacerbates lipopolysaccharide-induced cytokine release via TLR4 signaling in the enteric nervous system.Neonatal intrahippocampal HIV-1 protein Tat(1-86) injection: neurobehavioral alterations in the absence of increased inflammatory cytokine activation.Neonatal hippocampal Tat injections: developmental effects on prepulse inhibition (PPI) of the auditory startle response.Neonatal intrahippocampal injection of the HIV-1 proteins gp120 and Tat: differential effects on behavior and the relationship to stereological hippocampal measuresEffects of chronic adult dietary restriction on spatial learning in the aged F344 x BN hybrid F1 ratRegional heterogeneity and diversity in cytokine and chemokine production by astroglia: differential responses to HIV-1 Tat, gp120, and morphine revealed by multiplex analysisInteractive comorbidity between opioid drug abuse and HIV-1 Tat: chronic exposure augments spine loss and sublethal dendritic pathology in striatal neuronsInteractive HIV-1 Tat and morphine-induced synaptodendritic injury is triggered through focal disruptions in Na⁺ influx, mitochondrial instability, and Ca²⁺ overload.beta-Chemokine production by neural and glial progenitor cells is enhanced by HIV-1 Tat: effects on microglial migration.Effects of HIV-1 Tat on enteric neuropathogenesis.The effects of human immunodeficiency virus infection on the expression of the drug efflux proteins P-glycoprotein and breast cancer resistance protein in a human intestine modelSensitization of enteric neurons to morphine by HIV-1 Tat protein.Morphine potentiates neurodegenerative effects of HIV-1 Tat through actions at μ-opioid receptor-expressing glia.HIV-1 proteins, Tat and gp120, target the developing dopamine systemOpiate addiction therapies and HIV-1 Tat: interactive effects on glial [Ca²⁺]i, oxyradical and neuroinflammatory chemokine production and correlative neurotoxicity.Oligodendrocytes Are Targets of HIV-1 Tat: NMDA and AMPA Receptor-Mediated Effects on Survival and Development.Lateralized response of dynorphin a peptide levels after traumatic brain injury.Morphine efficacy is altered in conditional HIV-1 Tat transgenic mice.Opiate drug use and the pathophysiology of neuroAIDS.Morphine Tolerance and Physical Dependence Are Altered in Conditional HIV-1 Tat Transgenic Mice.Synaptic dysfunction in the hippocampus accompanies learning and memory deficits in human immunodeficiency virus type-1 Tat transgenic mice.Cannabinoids Occlude the HIV-1 Tat-Induced Decrease in GABAergic Neurotransmission in Prefrontal Cortex Slices.Differential expression and HIV-1 regulation of μ-opioid receptor splice variants across human central nervous system cell types.Differential long-term neurotoxicity of HIV-1 proteins in the rat hippocampal formation: a design-based stereological studyIntra-accumbal Tat1-72 alters acute and sensitized responses to cocaineDose-dependent long-term effects of Tat in the rat hippocampal formation: a design-based stereological study.Inhibition of GABAergic Neurotransmission by HIV-1 Tat and Opioid Treatment in the Striatum Involves μ-Opioid Receptors.Cue effects on memory for location when navigating spatial displays.HIV-1 Tat causes cognitive deficits and selective loss of parvalbumin, somatostatin, and neuronal nitric oxide synthase expressing hippocampal CA1 interneuron subpopulations.Neonatal intrahippocampal glycoprotein 120 injection: the role of dopaminergic alterations in prepulse inhibition in adult rats.Cue usage in memory for location when orientation is fixed.Intrahippocampal injections of Tat: effects on prepulse inhibition of the auditory startle response in adult male rats.Memory for spatial location: cue effects as a function of field rotation.Shape effects on memory for location.
P50
Q27303172-881002CB-80F0-4801-A215-5B6EB9233E7EQ27318687-7CA78EB4-3E68-4C94-9EBD-4C46E2B326D8Q30399828-464D50DA-A653-4BE7-99A0-D2236E370673Q30437301-29279B19-2DE6-4B2B-BFE4-29CAA2045DCDQ30486458-0C16B27B-3C4C-44DE-BA5F-103A2FAFEC3CQ33700976-73304106-D16B-4AC9-BEA8-E8FF7B978C89Q33797852-75B8985B-44B2-409C-8D48-E3CEFDF3846AQ34086976-C771699E-3D28-4833-999E-82E45379C276Q34197724-F64F11EA-4675-4149-B30D-7E4C1994AC10Q34356438-9FF34935-445B-45FF-9B5A-F24FA1528C8CQ34383417-DD41699F-0D37-4176-8F29-1A892FD0CAF2Q35013818-C264F8F8-E46C-4555-9F0D-202BE7E75D70Q35236345-B10583AA-D2A0-4983-8F5C-37FF30573CF8Q35606725-54403142-C086-498D-B8CC-4834CDDF2F24Q35743630-8CCBCBDB-363E-4760-B1E7-5CEDBBD5A915Q35763921-E1055F31-D110-4B62-9E0C-154356127452Q35941437-AD153AAD-8E4B-4D01-8E73-B5E02FCF01A0Q35989924-3FA393B9-F21A-4EE6-BFB0-AE68EC1C2E9DQ36109980-213BE9FB-A42A-42F7-BE1A-40CC7D1D5C93Q36201412-25902E95-85F7-445D-A851-0D35971EABAEQ36432328-E3058330-6E70-4784-93E3-4F8D7352277AQ36605014-684ECD12-D636-4C79-A3D5-5092962D14E8Q36844731-3BBE8FAE-D74D-4B02-8D39-D1D4EBD0E1FAQ37064333-A9E3F374-C238-415A-B668-7BF9A7BD9209Q37092361-FE414669-59E8-4BD0-B8DA-5E357EA7E84CQ37244423-ECCF14CA-7279-440E-95CE-13B7EEB5B45AQ37344253-7B0DE5F9-BCCD-4960-9313-DB4A13FA5222Q37399037-8E59AF4A-65FC-4B91-AC1C-2BB101F1D8DEQ42735730-7DBB44D3-8E80-4F4E-8E99-1C26F5F904CBQ45033937-5FCEC397-3E7D-48D0-AF30-81A69596D0F3Q45149767-300BD497-6B1B-4B1F-869B-584F439FB4BBQ46039759-4996FA99-190C-4F5C-B4C9-D36D7F164A38Q48491387-DD34E1D0-D133-446A-9103-E48FE697F9A7Q51969004-509602AC-5EC9-4FAF-99A4-53E3FF30BF74Q51970225-4B029913-E7B3-4850-8332-F3C5A8D24A30
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Sylvia Fitting
@ast
Sylvia Fitting
@en
Sylvia Fitting
@es
Sylvia Fitting
@nl
Sylvia Fitting
@sl
type
label
Sylvia Fitting
@ast
Sylvia Fitting
@en
Sylvia Fitting
@es
Sylvia Fitting
@nl
Sylvia Fitting
@sl
prefLabel
Sylvia Fitting
@ast
Sylvia Fitting
@en
Sylvia Fitting
@es
Sylvia Fitting
@nl
Sylvia Fitting
@sl
P106
P21
P31
P496
0000-0002-8906-3133